Compare M&T Bank Corporation (MTB) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs Sana Biotechnology Inc — how do they compare? M&T Bank Corporation trades at $251.93 (market cap $36.42B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: M&T Bank Corporation is far larger — about 32.2× Sana Biotechnology Inc's market cap, and M&T Bank Corporation pays a 2.38% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| MTB | SANA | |
|---|---|---|
Market Cap | $36.42B | $1.13B |
Sector | Financials | Health |
52-Week High | $254.04 | $5.92 |
52-Week Low | $178.63 | $2.68 |
Dividend Yield | 2.38% | — |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank (MTB) trades at $253.46, up 0.93% today, near its consensus price target of $255.92. The stock shows bullish technical momentum, with recent earnings consistently beating estimates, including Q2 2026 EPS of $5.35 versus $4.66 expected. Revenue growth is steady, with 2025 revenue at $9.63 billion and net income margin improving to 29.59%. The company maintains a solid dividend, paying $1.50 in H1 2026.
Outlook remains positive supported by strong fundamentals and analyst consensus, though risks include macroeconomic sensitivity and elevated investing cash outflows. The stock presents a value opportunity with a P/E of 13.35 and bullish institutional sentiment, but investors should monitor interest rate impacts and loan growth sustainability.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
